XOSPATA™
Brand Name: XOSPATA™
Composition: Gilteritinib (40 mg)
Manufacturer: Astellas
Product Description
Medical Info
XOSPATA™ 40 mg contains Gilteritinib, an advanced, targeted antineoplastic medication classified as a tyrosine kinase inhibitor. Developed by Astellas, this oral therapy is specifically indicated for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FMS-like tyrosine kinase 3 (FLT3) mutation. By selectively inhibiting FLT3 receptor signaling, XOSPATA™ works to block the abnormal pathways that promote the rapid proliferation and survival of malignant white blood cells. This highly specialized, film-coated tablet formulation plays a critical role in targeted hematology-oncology regimens under strict medical supervision
Storage & Safety
Precautions & Warnings
Reconstitute only with the prescribed quantity of clean drinking water. Shake well before each use. Complete the full course as prescribed. Discard any unused suspension after 7 days of reconstitution.
Storage
Store in a cool, dry place below 25°C. Protect from light and moisture. Refrigeration after reconstitution is preferred.
Status
Keep all medicines out of reach of children.
